Lexington Biosciences Inc. (LXGTF)

[maxcaviar]

this severe decline is just so hard to comprehend. the picture of the arm thingy had so many cool colors and buttons. go figure.

[Vesig]

So sad - I had high hopes for this company :/

[Stumblebum]

Can I answer with a minus number or percentage?

[betterdaze]

What’s the chances of a buyout for the patent?

[77Port]

Lex bio is truly dead. The company no longer exists. But the patent still exists, just don't know where it went. Whose desk drawer did it land in?

[Dollar Bill]

I was just wondering the same thing

[77Port]

Any insight as to why Lex stock is booming? Did they bring the Heart Sentry patent back from the dead?

[Dapper10]

This stock is junk. No creditably prior to RS. I lost a boat load. Management is not honest. Stay away.

[Dapper10]

This stock is junk. No creditably prior to RS. I lost a boat load. Management is not honest. Stay away.

[Randyfloyd420]

Lol junk

[Randyfloyd420]

Hello lol. Why’s no one here.

[Randyfloyd420]

Went from a penny to 8 cents in two days.

[Randyfloyd420]

How is nobody on this board??

[Randyfloyd420]

What’s goin on here today?

[maxcaviar]

yes, it's best to throw all of your money into a sh%tload of fecal discharge securities at this point. if it smells like a truck stop restroom on 2-for-1 chili night, you have reached the appropriate amount of accumulation.

[lukab]

Does LXGTF still make fecal discharge products for the con artist industry?

[RadarOReilly81]

The stock is coming back down to earth.

[MYOB]

No idea. I only need a couple more weeks like today and I'll begin to recover

[RadarOReilly81]

The stock is up 293% right now. Is there any real tangible news making this go up or is this the market makers having fun?

New CEO I see.

[MYOB]

is ANYTHING going on here?

[77Port]

PR pump full of more more pumping. Maybe this is next step to the latest pump project. Hey, what ever happened to the heart sentry patent? You'd think it would be relevant?
This press release is best read on a gassey stomach.

https://seekingalpha.com/pr/17840287?source=ansh $LXGTF
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (LXGTF) (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by the resignation of Eric Willis.

Since 1993, Mr. McInnes has been the founder, president and a director of a number of public natural resource companies. He is currently the Chairman of Sun Metals Corp. and a director of Liberty Gold Corp. and Lattice Biologics Ltd. Mr. McInnes was a Director of Fronteer Gold Inc., founder of Kutcho Copper Corp. (formerly Western Keltic Mines Inc.) and cofounder of True Gold Mining Inc. and True North Nickel Inc.. He was the founder and Vice Chair and CEO of Plutonic Power Corporation, that invested $1 billion in creating BC’s largest independent clean power company. Mr. McInnes is a past Chair of the Independent Power Producers Association of British Columbia, a past Governor of the Business Council of British Columbia, past President and Director of the Association for Mineral Exploration British Columbia, and past Director of the Prospectors and Developers Association of Canada. He is a recipient of AME BC’s Gold Pan Award, a lifetime Achievement Award from CEBC, an EY Entrepreneur of the Year Award and holds a Honorary Doctor of Technology Degree from BCIT.

On Behalf of the Board,

“Doug Janzen”

Doug Janzen
Chairman & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

CONTACT:
Lexington Biosciences, Inc.
[phone]
[e-mail]
www.lexingtonbiosciences.com

https://ml.globenewswire.com/media/861202c8-b4b0-4cdb-95ae-1fda7367f065/small/lexingtonbiologo-jpg.jpg

Source: Lexington Biosciences, Inc. 2020 GlobeNewswire, Inc.

[maxcaviar]

have no fear, 3 shares traded so far today. that's a cool 24 cents. a king's ransom in biblical times.

[77Port]

The LEXBIO weirdness gets weirder. Read today's article below to see Heartsentry being dropped like a hot potato. But where oh where did Heartsentry go? Where did the patent go? Who got it? This is a sleight of hand trick. Bait and switch. And the smoke screen of their "new direction," is simply odd. Maybe it's a good idea, but there is no recognition that the Heartsentry had 15 years of science behind it. Where is it? Where is the patent we shareholders own?

Read the latest weirdness:
https://www.globenewswire.com/news-release/2020/02/20/1988164/0/en/Lexington-Biosciences-Provides-Corporate-Update.html

Lexington Biosciences Provides Corporate Update

February 20, 2020 14:16 ET | Source: Lexington Biosciences, Inc.

VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) provides the following corporate update to shareholders.

HeartSentry Technology

The Company had been unable to secure the necessary financing to advance the development of the HeartSentry technology including the payment of the minimum annual royalty fees due, in August 2018 and August 2019, to the Lawrence Berkeley National Laboratories. As a result, on February 12, 2020, the company received final notice of license termination from Lawrence Berkeley National Laboratories due to non-payment of these minimum annual royalty fees. 

Change in Business

The Company has called for a Special and Annual General Meeting to be held on March 30, 2020, where, amongst other items, the shareholders will vote on amending the Company’s Notice of Articles and Articles to create several classes of tracking shares in order to facilitate the Company becoming a Private Investment Platform Company (the “New Business”).

Once complete, the New Business will allow investors, to use their Registered Plans (including registered retirement savings plans, registered education savings plans, tax free savings accounts, registered retirement income funds, and registered disability savings plans), at their own direction, to invest in private companies by purchasing tracking shares in the Company, which will in turn use these proceeds to invest in the specific private company chosen by the investor.

The Company will charge investors fees for the initial investment and redemptions as well as an annual fee based on amount invested. Additional information on the New Business will be included in the Information Circular for the Special and Annual General Meeting which will be mailed to shareholders in early March, 2020.

To reflect the New Business, the Company will be changing its name to “Registered Plan Private Investments Inc.”.

Non-Brokered Private Placement

The Company announces that it intends to sell, by way of a non-brokered private placement up to 10 million units of the Company (“Units”) at a price of $0.05 per Unit for gross proceeds of up to $500,000 (the “Offering”). Each Unit will consist of one common share of the Company and one common share purchase warrant (each, a “Warrant”). Each Warrant will be exercisable to buy one common share of the Company for a period of 24 months at a price of $0.07.

The Company intends to use the net proceeds of the Offering to complete the necessary steps to convert to the New Business. The Offering is subject to the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued pursuant to the Offering will be subject to a four-month hold period in accordance with applicable Canadian securities law.

Conversion of Unsecured Demand Loans into Units

The Company previously announced that it had reached agreement with third parties as well as certain directors and officers (collectively the “Lenders”) of the Company to convert previous advances and unpaid amounts for services received and interest accrued therein for approximately $800,000 including interest into demand loans.

Subject to shareholder approval at the upcoming Special and Annual General Meeting, the Lenders have agreed to convert the full amount owing in to Units on the same terms as the upcoming Non-Brokered Private Placement.

Change in Directors and Management

The Company also announces the resignation of Eric Willis as CEO and Director of the Company. The Company wishes to thank Mr. Willis for his service.

Canadian Securities Exchange Listing

As part of the Special and Annual General Meeting, shareholders will be asked to vote on a resolution to de-list the Company’s shares from the Canadian Securities Exchange.

On Behalf of the Board,

“Doug Janzen”

Doug Janzen
Chairman & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

CONTACT:
Lexington Biosciences, Inc.
[phone]

© 2020 GlobeNewswire, Inc. All Rights Reserved.

[77Port]

The best of the bad news is that the POS CEO Eric Willis is gone. He seemed unable to do anything right, completely incompetent. Now that Berkeley lab is gone, and that's as bad as it gets, can they regain what's owed by taking any ownership of the product or patent? Seems like the LEXBIO idea was thought up at a drunken party with the gold and lithium miners of the parent company. Bunch of crooked actors.

[doczaius]

Not surprising. Seems to me if the heart sentry had the potential we were made to believe, they could have secured some financing. Pumped garbage.

[77Port]

https://www.globenewswire.com/news-release/2020/02/13/1984247/0/en/Lexington-Biosciences-License-Terminated.html

Lexington Biosciences License Terminated

February 12, 2020 21:13 ET | Source: Lexington Biosciences, Inc.

VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) has allowed the license with the Lawrence Berkeley National Laboratories, which was being used in the HeartSentry technology, to terminate due to non-payment of its minimum annual royalty fees which were due in August 2018 and August 2019.

As previously announced in April, 2019, the Company had been unable to secure the necessary financing to advance the development of the HeartSentry technology. Since that date, the Company has actively been in discussions with potential development partners to sell the HeartSentry license and intellectual property, which ultimately have not been successful. As a result, on February 12, 2020, the company received final notice of license termination from Lawrence Berkeley National Laboratories due to non-payment of its minimum annual royalty fees.

The Company has identified a new business plan and is currently negotiating with its largest unsecured creditor on terms of debt conversion. The feasibility of the new business plan is conditional on successfully negotiating a debt settlement.

The Company also announces the resignation of Eric Willis as its CEO & Director.

On Behalf of the Board,

“Doug Janzen”

Doug Janzen
Chairman & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements relating to the potential sale of the HeartSentry technology and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include those relating to the ability to complete the sale and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

CONTACT:
Lexington Biosciences, Inc.
[phone]
Lexington Biosciences, Inc.
 Vancouver, British Columbia, CANADA
  https://lexingtonbiosciences.com/

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

© 2020 GlobeNewswire, Inc. All Rights Reserved.

[77Port]

Incompetence or corruption, not sure which is more accurate. This article, years ago, would have triggered all sorts of fantasies:

Tech giants have big ambitions in health, but do best when they stick to what they know - https://www.cnbc.com/2019/12/31/amazon-google-apple-and-other-giants-humbled-by-health-tech-failures.html

[lukab]

Haven't thought about this disgusting pile of manure company for a while. Anybody know what is going on with this stench now? thanks

[5bjjamie5]

Who are the lenders? The insiders or actual investors? If it’s inside holders, will they make a “demand” for payment?

[77Port]

This is a long-shot speculation, but since the company is mute, speculation becomes a form of life.

The article below is about the Bridgemark scandal which is one of the reasons all Canadian pot stocks have been eviscerated in the past months. While unrelated to LEX, two touch points may vibrate and even a loose vibration might make big money evaporate. The Bridgemark bleeding is still being investigated as big money identifies who is stained and dies and who is not stained and can survive the slow bleeding. Only the strong survive, right?

What might the loose connection be? Here are two:
1. A couple of years ago Lex was tagged as a potential pump and dump and ended up on a list with some of the companies involved in the Bridgemark scandal. Coincidence or deserved? Who knows?
2. This is from this article below: "Why are all of these companies using 1199 West Hastings Street Vancouver?"

Does anybody remember LEX's Vancouver address. One block away:
1055 W. Hastings St., Suite 1900, Vancouver, BC Canada V6E 2E9.

Yes, it's a loose connection. But scandal terrifies big money and they flee first and find out facts second. And the truth is that smell attracts. Bridgemark certainly stinks to high heaven. LEX isn't exactly odor free either.

https://equity.guru/2019/08/08/abattis-bioceuticals-att-c-grift-building-several-years-regulators-couldnt-ignore-anymore/?fbclid=IwAR30S33J3QOFNE_5xZV98DqxklD---Ky4naLpO2Xxqi30UVT7aOqBYOjebI

And if nothing else, this is actually an interesting article about the tumor-ridden underbelly of the penny stock world.

[maxcaviar]

it's just my speculation. but this sort of scenario happens all the time and there's rarely a happy ending for the retail investors.

[Tiredofbanks]

I dont think thats what its saying. Its saying the people that loaned the $744k are getting a demand loan which means they can demand repayment at any time, and to compensate they are offering them Warrants instead that they will have up to 2 years to exercise the option of making those warrants into common shares at a value of .05 cents no matter what the stock price is at the time they decide to exercise them. So if say the stock went up to .20 cents they could still take their shares at .05 cents and profit .15 cents if they sold them at .20 cents instantly (per share) The amount of shares they can get at .05 cents add up to the demand loan amount of 744k. So they either demand the money or take the shares depending on how the stock would be doing. This will hold off the current money they are in debt. What they do from this point on is the question to advance the Heart Sentry and possibly the stock. Sell it? maybe. But they must be trying to do something with it for the lenders to agree to the possible warrants as an option. Still a crap shoot as to what will happen.

[77Port]

Correct me if I'm wrong, but this piece of news from last October seems to give people imaginary shares to cash out at 5 cents a pop. Does that mean once the 14 million "bonus" warrants are all cashed out, and once these folks get their "loans" repaid, does the whole lie then collapse? I find it hard to believe the Heart Sentry is simply sitting in a drawer somewhere. Don't they have any obligation to tell us what's going on? Is there any way to find out? Is there an ombudsman, or something, to ask such a question to? The company is moot, so what is there to be done?

Isn't this simply designed to suck all funds until all LXGTF accounts are empty?

VANCOUVER, BRITISH COLUMBIA – October 4, 2019 – Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) announces that it has reached agreement with third parties as well as certain directors and officers (collectively the “lenders”) of the Company to convert previous advances and unpaid amounts for services received of $654,186, in aggregate, into unsecured demand loans bearing interest at 16% per annum. As a result of the interest being applied retroactively to the date the advances or services were made the Company owed these parties $744,203 as at September 30, 2019, which is the aggregate amount of the unsecured demand loans issued.

In consideration for the conversion of the advances into unsecured demand loans, the Company will issue a total of 14,880,465 bonus warrants (“Warrants”) to the lenders at a deemed price per share of $0.05. The Warrants will be exercisable for a period of 24 months into common shares of the Company at a price of $0.05 each.

On Behalf of the Board,

“Eric Willis”

Eric Willis
CEO & Director

[77Port]

Delisting?

[maxcaviar]

delisting, followed by crickets

[Tiredofbanks]

just waiting to see what happens.

[doczaius]

Anybody still here?

[Dapper10]

Who would ever buy 30,000 shares? They have to be absolutely crazy. He just wasted $1500.00 dollars. Just nuts.

[Dapper10]

Hope all officers rot in hell.

[77Port]

Saw that, too. Maybe they're cleaning up the burnt ends to make a sale? If so, hope we end up with company stock of whover buys the patent and heart sentry technology.

[moncam]

Greetings to each of you and the best to ALL of us.

News Releases
04/10/2019
Lexington Biosciences Converts Amounts Owed to Unsecured Demand Loans is now posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under News.

Lexington Biosciences, Inc.
Suite 1900, 1055 West Hastings Street
Vancouver, British Columbia, Canada V6E 2E9
Lexington Biosciences Converts Amounts Owed to Unsecured Demand Loans
VANCOUVER, BRITISH COLUMBIA – October 3, 2019 - Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) announces that it has reached agreement with third parties as well as certain directors and officers (collectively the “lenders”) of the Company to convert previous advances and unpaid amounts for services received of $654,186, in aggregate, into unsecured demand loans bearing interest at 16% per annum. As a result of the interest being applied retroactively to the date the advances or services were made the Company owed these parties $744,203 as at September 30, 2019, which is the aggregate amount of the unsecured demand loans issued.
In consideration for the conversion of the advances into unsecured demand loans, the Company will issue a total of 14,880,465 bonus warrants (“Warrants”) to the lenders at a deemed price per share of $0.05. The Warrants will be exercisable for a period of 24 months into common shares of the Company at a price of $0.05 each.
On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO & Director
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements relating to the potential sale of the HeartSentry technology and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include those relating to the ability to complete the sale and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward- looking statements as expressly required by applicable law.
CONTACT:
Lexington Biosciences, Inc.
[phone]
[e-mail]
www.lexingtonbiosciences.com

[Tiredofbanks]

All stocks are giving a number identifier sort of like people get a social to identify them. They use the ticker symbols for ease of recognition for investors. Sometimes they will show the number possibly when something has occurred like when lex did a reverse split. Until they post the new ticker info that represents the change. Not sure what stock you refer to or what would be happening.

[MYOB]

ALERT: Ignorance Question, please tolerate my ignorance. This has nothing to do with Lex(so far)
What does it mean when a stocks symbol is replaced with a 9 digit alpha numeric symbol?
TIA

[77Port]

I hope the Heart Sentry is still in people's imagination. I clicked on a link and found this article about Omron, one of the world's largest blood pressure monitoring companies.

If only Lex would have been imaginative enough to think of this kind of partnership, this might be an entirely different conversation.

This fact remains: the Heart Sentry patent remains intriguing. And this article remains exciting, too:

https://www.lark.com/press-articles/2019/9/17/ai-health-coaching-with-bp-monitoring-causes-significant-bp-reduction

[MYOB]

volunteering for helper position to make that woodshed moment happen.

[Dapper10]

Totally agree with you likable. Worst management team ever. To bad we didn’t have a better team b/c I believe the product had great potential. The bio’s on everyone was totally bogus. They all need to be taken behind the woodshed for a good whooping.

[lukab]

That would be awesome Dapper but I'm sure these weasels would just hide under their desks. This is the most pathetic stock investment I've ever had. Dear God, why did I ever have to even hear about this pitiful company!

[Dapper10]

I believe I need to take a trip and visit our CEO. He needs to personally hear from one of us. We have gone through a lot of pain since they destroyed many bank accounts.

[doczaius]

Yeah I went from 62,000 shares @.097 to 6,200 shares at .03 and next probably zero. If the damn thing just didn't work that's one thing but if was a con job like you said 77 then they should be sued and go to jail

[77Port]

.03 USD. That is what our stock is worth. But the question remains the same: is the Heart Sentry real or fake? If real, then the story remains, regardless of price. If real, the price doesn't reflect the tech and patent but reflects the incompetence of this company.
But if Heart Sentry is a fake product, then it will be a bankrupt failure and we all lose our money. If it's fake, we should locate an attorney willing to file a class action suit against LEXs parent and related companies. I dont think corps protect against fraud.

If the story remains real, then this dark time could be a manipulative rebalancing in order to move shares into the hands of those who want to end up with the patent. Second question: if real, will the new owners/powers allow us to stay involved. Or will they force a bankruptcy to finally get rid of us because they want to rid themselves of all things LEX? Cynical, yes, but companies have done such dastardly things before.